Tamoxifen Tales

V. Craig Jordan is Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer. In 2019 he was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II for services to women’s health.

1. Beginnings
2. The University of Leeds: Foundation of a Career
3. The Chance to be a PhD Student at The University of Leeds
4. Two Antiestrogenic Strategies to Treat Breast Cancer at the Worcester Foundation
5. A New Strategy: Long-Term Adjuvant Tamoxifen Treatment and Other Discoveries at the University of Leeds
6. Tamoxifen’s Patenting Problems in America, Which Created a “Cancer Treatment Company”
7. Two Opportunities in Different Continents
8. The Good, The Bad and the Ugly of Tamoxifen at Wisconsin
9. “Sliding Door” and Serendipity
10. South to Northwestern in Chicago
11. Forward to the Fox Chase Cancer Center in Philadelphia
12. Get out and Go to Georgetown, Washington, DC
13. Closing the Circle of Tamoxifen Tales?
14. “If I Wanted to Buy Your Brain, What Would That Cost?”: Rebirth at MD Anderson
15. Invest in the Young
16. Scientific Survival Suggestions
17. An Account of PhD Students over 50 years of Tamoxifen Teams
18. Case Studies: In Their Own Words